Lucy Therapeutics
Nelli is an Associate Professor at Penn State University College of Medicine, where her research focuses on investigating the molecular identity, structure, and function of the enigmatic cell death channel, the mitochondrial permeability transition pore, and its role in Alzheimer's disease. She is the recipient of the Biophysical Society Young Bioenergetics award and a Career Development award from the National Institute on Aging.
This person is not in the org chart
This person is not in any offices
Lucy Therapeutics
Lucy Therapeutics is offering a differentiated and novel approach to drug discovery by drugging targets associated with early disease pathogenesis. LucyTx’s unique approach recognizes that improvement of mitochondrial function early in disease will lead to disease modification as opposed to late-stage symptomatic treatments being pursued by many others. Mitochondrial improvement effects multiple downstream effectors that are essential to disease initiation and progression. Our targets have been validated as neuroprotective in multiple animal models. Key to our strategy is a novel dosing regimen which will mimic effects known to be protective for both neurological and cardiovascular events implicated in key CNS diseases. LucyTx proposes to focus on the orphan disease Rett Syndrome for a proof of concept; we will also explore applications of our technology to Parkinson’s and other CNS diseases.